SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Shiba Inu (SHIB) is a decentralized, community-led cryptocurrency ecosystem built on the Ethereum blockchain. Originally launched as a meme-based project, it has evolved into a comprehensive financial ecosystem designed to offer a decentralized alternative to traditional banking. Its main value proposition lies in its transition from a social phenomenon into a functional utility network, supported by a vast global community known as the ShibArmy and a commitment to 100% community ownership with no central leadership.  The ecosystem features its own decentralized exchange, ShibaSwap, where users can trade, provide liquidity, and earn rewards. To address Ethereum’s high costs and slow speeds, the project utilizes Shibarium, a Layer 2 scaling solution that processes transactions faster and more affordably.  The project employs a unique three-token model to manage its economy and governance. SHIB serves as the primary currency for trading and payments, while LEASH offers scarcity-based incentives for dedicated supporters. BONE acts as the governance token, allowing holders to vote on proposals through the Doggy DAO and serving as the native gas token for the Shibarium network.

Shiba Inu

Shiba Inu is currently a focal point of intense community debate, with holders balancing optimistic speculation regarding potential supply burns and institutional status against widespread skepticism about its long-term performance. While some participants view current price levels as a strategic accumulation zone, others remain vocal about the asset's volatility and its historical correlation with broader market downturns.

What is the project about? Pepe is a community based meme token surround the iconic meme Pepe the frog. Pepe aims to leverage the power of such an iconic meme to become the most memeable memecoin in existence.   What makes your project unique? Pepe is here to make memecoins great again. Ushering in a new paradigm for memecoins, Pepe represents the memecoin in it's purest simplicity. With zero taxes, liquidity locked forever, and contract immutable, Pepe is for the people, forever. Pepe is about culture, rallying together a community to have fun and enjoy memes, fueled purely by memetic power.   History of your project. Pepe was stealth launched on Friday, April 14th, 2023.   What’s next for your project? Pepe will focus on developing a tight-knit community around the token and building resources to enrich the communities knowledge and success in crypto through a token gated group, newsletter, and more tools.   What can your token be used for? Pepe can be used to speculate on the power of memes, and does not pretend to be anything more.

Pepe

Pepe is seeing renewed market attention as traders monitor potential institutional interest and ETF speculation, fueling community debates over whether it can replicate its past breakout momentum. While some participants express frustration with price volatility and the broader memecoin landscape, others view the current consolidation as an accumulation phase in anticipation of a potential market-wide recovery tied to broader crypto sentiment.

Bonk is a dog-themed memecoin on the Solana blockchain, launched on Christmas Day 2022 to revitalize the Solana community following the FTX collapse. Created by an anonymous team of 22 Solana developers and builders, Bonk distributed 50% of its total 100 trillion token supply via airdrop to community members including NFT collectors, developers, and artists.   The project positions itself as "the first Solana dog coin for the people, by the people," explicitly rejecting venture capital backing in favor of grassroots community ownership. What sets Bonk apart from other memecoins is its combination of fair launch mechanics, extensive ecosystem integration, and active deflationary strategy.   Built on Solana, BONK benefits from fast transaction speeds and low fees that make it practical for everyday use. Native products include LetsBonk.fun (a memecoin launchpad that briefly became Solana's market leader in 2025, surpassing Pump.fun with over 78% market share), BonkSwap (a decentralized exchange) and BonkBot (a Telegram trading bot with built-in burn mechanics).   BONK is available across 10 blockchain networks and listed on major exchanges including Binance, Coinbase, Kraken, and Robinhood. Governance is handled by BonkDAO, which holds 15% of the token supply and makes decisions through on-chain voting.   The community has organized several major burn events, most notably the December 2024 BURNmas campaign that destroyed 1.69 trillion tokens worth over $50 million. In September 2025, Nasdaq-listed Safety Shot, Inc. formed BONK Holdings LLC and acquired over 2.5% of the circulating supply (valued at $55-63 million), making BONK one of the first memecoins to attract formal corporate treasury adoption. Core contributor Nom was appointed to Safety Shot's board, and the company holds a 10% revenue share in LetsBonk.fun.  As with all memecoins, BONK is a highly speculative asset with substantial volatility. Its value is primarily driven by community sentiment, social media momentum, and meme culture rather than traditional utility.   The anonymous team, while common in the memecoin space, means investors should exercise appropriate caution. Despite these risks, Bonk has established itself as one of the most successful community-driven tokens in the Solana ecosystem, approaching 1 million unique holders and expanding from a simple memecoin into meaningful DeFi infrastructure.

BONK

BONK is experiencing heavy social media activity, with the community polarized between those aggressively accumulating during recent price volatility and skeptics dismissing it as a typical memecoin pump-and-dump cycle. Investors are closely monitoring key metrics like chain holder growth and upcoming token burn events, while sentiment remains highly volatile as the asset navigates broader market consolidation.

What Is Tezos (XTZ)?   Tezos is a high-performing blockchain and open-source platform for assets and applications, with a strong focus on code security, on-chain governance, and decentralization. Tezos 2.0, the upcoming step in the evolution of Tezos, aims to improve scalability (via layer 2s), composability, and to implement support to mainstream programming languages (like Javascript, Typescript, Python, and many others).   Initially built with formal verification in mind, the Tezos protocol enables builders to avoid bugs when developing smart contracts, making it particularly suited to applications that require a high degree of security and certainty.   Tezos’ LPoS (Liquid Proof-of-Stake) consensus mechanism enables any stakeholder to take part, directly or by delegation, in the consensus process, and to be rewarded for securing the network. Rather uniquely, Tezos’ on-chain governance system also enables stakeholders to create and vote on protocol upgrade proposals. This pioneering system allows the protocol to self-amend and upgrade itself without leading to a split (or fork) in the blockchain, empowering the community without slowing down innovation.   First proposed in 2014 and launched in 2018, the Tezos Mainnet has a proven track record of running uninterrupted ever since, having earned a strong reputation for technical excellence and a supportive community.    Who Are the Founders of Tezos? Tezos was conceived by Arthur and Kathleen Breitman in a 2014 white paper under the pseudonym L.M. Goodman in a nod to Satoshi Nakamoto, referencing a journalist who had misidentified the creator of Bitcoin.   In a previous paper, the Breitmans had argued that Bitcoin's biggest shortcomings were the lack of a governance process that invited contributions from its community of users, cost and centralization issues raised by its proof-of-work system, the limited expressiveness of its programming language which didn’t allow for smart contracts, and security

Tezos

Tezos is trending as active traders debate whether recent volatility and chart patterns signal a potential recovery or further downside, with a polarized community split between long-term holders anticipating a bull cycle and skeptics calling for lower support levels. Market discussions remain heavily focused on the interplay between technical momentum, staking rewards, and broader macroeconomic factors impacting alternative assets.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Summit Therapeutics is attracting significant attention as investors anticipate key regulatory milestones, specifically an upcoming FDA decision for ivonescimab. While some community members express frustration with recent price volatility and delays, others remain deeply bullish, pointing to strong trial data and a potential short squeeze as major catalysts for future growth.

Cardano is a blockchain platform built on academic research that enables smart contracts and decentralized applications while using significantly less energy than traditional cryptocurrencies like Bitcoin.   What sets Cardano apart is its methodical, research-driven approach — every major feature is peer-reviewed by scientists and cryptographers before being added to the network. This careful process aims to create a more secure and stable foundation compared to platforms that prioritize speed over thorough testing. The platform's native cryptocurrency, ADA, is used to send money, pay transaction fees, and participate in network governance.  Cardano uses a proof-of-stake system to process transactions, which works differently from Bitcoin's mining approach. Instead of competing to solve complex puzzles, users can "stake" their ADA — essentially locking it up temporarily — to become validators who verify transactions. The system selects validators based on how much ADA they've staked and for how long, then rewards them with additional ADA for their participation. This approach uses far less energy than traditional mining while keeping the network secure. The platform also features a two-layer design that separates basic payment transactions from smart contract operations, allowing each function to be optimized independently for better performance.   ADA holders can earn staking rewards by locking up their tokens to help secure the network, vote on proposed changes to the platform, and use ADA for international money transfers with lower fees than traditional services.  Cardano was founded in 2017 by Charles Hoskinson, who previously helped create Ethereum. Hoskinson leads Input Output Global (IOG), the technology company that builds and maintains Cardano's core software. The ecosystem operates through three organizations: IOG handles technical development, the Cardano Foundation promotes adoption and standardization, and Emurgo helps businesses integrate blockchain technology into their operations. This structure distributes responsibilities across multiple groups rather than concentrating control in a single entity.   In February 2025, major asset manager Grayscale Investments filed to create an exchange-traded fund (ETF) for Cardano with the U.S. Securities and Exchange Commission, which would allow traditional investors to buy ADA through their regular brokerage accounts without needing to set up cryptocurrency wallets.Retry

Cardano

Cardano is experiencing intense volatility, with investors debating whether current price levels present a buying opportunity or a signal of deeper long-term decline. Sentiment remains polarized as traders closely monitor technical support zones and potential regulatory updates, leading to active discussions about whether the asset is accumulating for a future breakout or facing a prolonged bear market.

"What's Updog?" is a Community Led token.

UpDog

The UpDog ($UPDOG) community is driving significant momentum across social channels by leveraging engagement-heavy strategies and meme-focused community building on the Solana blockchain. Investors and community members are actively discussing the project's long-term presence in the market while coordinating efforts to increase awareness and drive adoption through persistent social signaling.

Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. Its products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. The company was founded in 2013 and is headquartered in San Diego, CA.

Arcturus Therapeutics Holdings Inc

Arcturus Therapeutics is facing significant volatility following mixed interim Phase 2 data for its inhaled cystic fibrosis therapy, ARCT-032, where investors are debating whether the observed mucus reduction justifies the lack of meaningful lung function improvement. While some market participants express concern over the stock's sharp decline, others are actively discussing a potential rebound, pointing to the company's solid cash position, ongoing influenza vaccine programs, and the possibility of undervalued assets triggering interest from larger biotech players.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Johnson & Johnson

Johnson & Johnson is seeing heavy activity as investors react to a mix of new FDA approvals for its oncology portfolio and ongoing legal developments, including significant talc-related litigation. The company is simultaneously focused on long-term growth through pipeline expansion and major U.S. manufacturing investments, while dividend-focused investors continue to monitor its defensive posture amid broader market volatility.

The Coca-Cola Co. engages in the manufacturing and marketing of non-alcoholic beverages. It operates through the following segments: Europe, Middle East and Africa, Latin America, North America, Asia Pacific, Global Ventures, and Bottling Investments. The company was founded by Asa Griggs Candler on May 8, 1886 and is headquartered in Atlanta, GA.

Coca-Cola Co

Coca-Cola is trending as investors favor its defensive stability and reliable dividend growth, with ongoing community discussion highlighting it as a classic 'sleep-well-at-night' holding during periods of market uncertainty. Furthermore, the stock continues to attract attention from analysts and traders alike due to its technical breakout, long-term performance consistency, and its role as a core component in many defensive-focused investment strategies.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

MiNK Therapeutics, Inc. (NASDAQ:INKT) Given Average Recommendation of "Hold" by Brokerages

MiNK Therapeutics, Inc. (NASDAQ:INKT - Get Free Report) has received a consensus rating of "Hold" from the five research firms that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, two have given a hold rating, one has assigned a b...

HC Wainwright Issues Positive Outlook for INKT Earnings

MiNK Therapeutics, Inc. (NASDAQ:INKT - Free Report) - Equities researchers at HC Wainwright increased their Q1 2026 earnings per share estimates for shares of MiNK Therapeutics in a note issued to investors on Wednesday, April 1st. HC Wainwright analyst E. Bodnar now expects that the company will po...

MiNK Therapeutics Q4 Earnings Call Highlights

MiNK Therapeutics (NASDAQ:INKT) outlined progress across its allogeneic invariant natural killer T-cell (iNKT) platform during its fourth quarter and year-end 2025 financial results conference call, highlighting updated clinical observations in solid tumors, plans to initiate randomized testing in s...

MiNK Therapeutics (NASDAQ:INKT) Director Barbara Ryan Sells 1,300 Shares

MiNK Therapeutics, Inc. (NASDAQ:INKT - Get Free Report) Director Barbara Ryan sold 1,300 shares of MiNK Therapeutics stock in a transaction that occurred on Tuesday, March 10th. The shares were sold...

Why Is MiNK Therapeutics Stock Trading Lower On Wednesday?

MiNK Therapeutics stock drops after a 30% rally as investors react to profit taking and a $1.1 million pediatric cancer therapy deal.read more...

Strategic Partnerships and Platform Plays Power New Momentum Across Tech and Healthcare

Markets open the session with strategic partnerships, infrastructure consolidation, and breakthrough technologies dominating the corporate news cycle; several companies are positioning themselves at the intersection of innovation and scalable commercialization. $INKT, $VTAK, $KBLB, $APP, $BEAT, $SGN, $STGW

MiNK Therapeutics Pediatric Cancer Breakthrough Sparks Stock Rally

MiNK Therapeutics' stock rises premarket after announcing a pediatric cancer cell therapy collaboration with C-Further and $1.1 million funding.read more...

<ul class="summary-bullets"><li>The program will focus on a PRAME-targeted TCR-engineered invariant natural killer T cell therapy to treat pediatric tumors.</li><li>The program will receive around $1.1 million in funding to support its early-stage development.</li><li>The agreement provides for a double-digit share of future commercial revenues.</li></ul>Shares of MiNK Therapeutics (INKT) gave up most of their early gains to trade 32% higher on Tuesday after the company announced a collaboration with the C-Further, an oncology consortium, to develop a cell therapy targeting pediatric cancers.The program will focus on a PRAME-targeted TCR-engineered invariant natural killer T (iNKT) cell therapy to treat pediatric tumors. Preferentially Expressed Antigen in Melanoma, or PRAME, is a tumor antigen found in several cancers.MiNK’s iNKT platform aims to address key limitations of traditional cell therapies, which require patient-specific manufacturing and long preparation times.&nbsp;The therapy is derived from healthy donors and can be produced in advance, stored, and delivered when needed without complex matching or intensive pre-treatment. This approach could allow faster treatment and broader access, especially for children with aggressive cancers, the company said.&nbsp;<h2 class="st-heading-2">Program To Receive $1.1 Million In Funding</h2>By combining PRAME-targeting with MiNK’s iNKT cell platform, the therapy aims to precisely attack tumors while also activating broader immune responses.The program will receive around $1.1 million in funding to support its early-stage development, and the agreement also provides for a double-digit share of future commercial revenues, the company added.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment for <a href="https://stocktwits.com/Breakoutstockmoves/message/647092507">INKT</a> on Stocktwits turned 'extremely bullish' from 'bullish' a day earlier, amid 'extremely high' message volumes.&nbsp;<img src="https://news.stocktwits-cdn.com/INKT_jpg_8148d6ae77.webp" alt="INKT.jpg">One user saw support at $13.5.<stembedurl>https://stocktwits.com/cjwaters14/message/647135253</stembedurl>Another user said the $1 million funding was a "small teaser" ahead of a potential buyout.<stembedurl>https://stocktwits.com/Breakoutstockmoves/message/647092507</stembedurl>Year-to-date, the stock gained 24%.For updates and corrections, email newsroom[at]stocktwits[dot]com

Representative image of a trending stock chart.

Why Did INKT Stock Jump 30% Today?

MiNK Therapeutics tied up with an oncology consortium to develop a cell therapy targeting pediatric cancers.

Equity

MiNK Therapeutics, Inc. (NASDAQ:INKT) Receives Consensus Rating of "Hold" from Brokerages

Shares of MiNK Therapeutics, Inc. (NASDAQ:INKT - Get Free Report) have received an average recommendation of "Hold" from the five ratings firms that are presently covering the stock, MarketBeat.com...

MiNK Therapeutics, Inc. (NASDAQ:INKT) Receives Consensus Recommendation of "Hold" from Analysts

Shares of MiNK Therapeutics, Inc. (NASDAQ:INKT - Get Free Report) have been given an average rating of "Hold" by the five research firms that are currently covering the company, MarketBeat Ratings...

MiNK Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of allogeneic invariant natural killer T cell therapies to treat cancer and other immune mediated diseases. The company was founded in 2017 and is headquartered in New York, NY.

INKT
MiNK Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest INKT News

INKTMiNK Therapeutics Inc